U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07106827) titled 'A Study of GV20-0251 in Advanced or Refractory Solid Tumors' on July 09.

Brief Summary: This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively. The cancer types include solid tumors.

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: HCC - Hepatocellular Carcinoma Cholangiocarcinoma Melanoma NSCLC (Non-small Cell Lung Cancer) Pancreatic Ductal Adenocarcinoma HNSCC Endometrial Cancer Testicular Cancer

Intervention: DRUG: GV20-0251

Increasing doses of GV...